BrightHeart has raised €11m ($12.8m) in funding to advance commercialisation efforts for its artificial intelligence (AI)-based prenatal congenital heart defect (CHD) screening platform.
The French company’s B-Right platform uses AI to identify structural markers suggestive of CHDs in second‑trimester fetal ultrasound images. The platform received US Food and Drug Administration (FDA) clearance in November 2024. In 2025, BrightHeart received additional clearances for software that allows practitioners to access B-Right analysis in real-time through a cart-side tablet.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
BrightHeart plans to use the latest funding to expand B-Right’s presence across healthcare facilities in the US. As of 2025, the platform is currently in use at a limited range of facilities, including New York’s Mount Sinai Hospital.
BrightHeart’s Series A financing round was co-led by venture capital (VC) firms Odyssée Venture and GO Capital, with participation from other investors including Mussallem CHD Alliance, Lift Value, and founding investor Sofinnova Partners.
BrightHeart CEO Cécile Dupont commented: “This new round of funding empowers us to accelerate BrightHeart’s mission of making AI the new standard of care in prenatal ultrasound. Our goal is to enhance diagnostic accuracy, improve outcomes for families and babies, and streamline clinical workflows for healthcare professionals.”
In January 2025, BrightHeart presented data from two studies at the 2025 Society for Maternal-Fetal Medicine (SMFM) Pregnancy Meeting in Colorado. A study of 200 prenatal ultrasound exam datasets revealed that BrightHeart’s AI software improved detection rates with a 15.3% increase in sensitivity. The software also improved efficiency, with an 18% reduction in read time among specialists.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataResearch indicates that CHDs impact one in 100 live births worldwide. However, with 70% of cases requiring treatment in the first year of life, more than 90% of cases in low- and middle-income countries receive no treatment or suboptimal treatment.
According to GlobalData analysis, open heart surgery is the most common approach to correcting CHDs, although minimally invasive techniques have been steadily progressing in recent years.
AI is having a strong influence in the healthcare space, with GlobalData analysis forecasting that AI in healthcare is forecast to reach a $19bn valuation by 2027.
BrightHeart is one of many companies to harness AI in medical imaging, one of the technology’s most prominent areas of adoption in healthcare. Speaking to Medical Device Network in 2025, Marissa Fayer, CEO at DeepLook Medical, described the potential applications of AI in imaging as “endless”.
In 2025, HeartFlow, the developer of an AI-based platform to more accurately assess patients with arterial plaque buildup (atherosclerosis), completed a $364m initial public offering (IPO). According to observers, the success of the US company’s IPO reflects AI’s ‘complete validation’ by the market.
